Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report $1.48 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for Regeneron Pharmaceuticals’ earnings. The highest sales estimate is $1.53 billion and the lowest is $1.41 billion. Regeneron Pharmaceuticals reported sales of $1.23 billion in the same quarter last year, which would suggest a positive year over year growth rate of 20.3%. The firm is expected to report its next earnings report on Thursday, February 8th.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $1.48 billion for the current fiscal year, with estimates ranging from $5.69 billion to $5.81 billion. For the next fiscal year, analysts anticipate that the company will report sales of $6.24 billion per share, with estimates ranging from $5.89 billion to $6.76 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter last year, the business posted $3.13 earnings per share. The company’s quarterly revenue was up 23.0% on a year-over-year basis.
REGN has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $490.00 price target (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Jefferies Group reiterated a “hold” rating and issued a $500.00 price target (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. SunTrust Banks reiterated a “hold” rating and issued a $435.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, October 2nd. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $471.11.
A number of institutional investors have recently made changes to their positions in the stock. Fieldpoint Private Securities LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $130,000. Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $200,000. Virtu KCG Holdings LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $206,000. Moors & Cabot Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $217,000. Finally, People s United Financial Inc. raised its stake in shares of Regeneron Pharmaceuticals by 656.7% during the 2nd quarter. People s United Financial Inc. now owns 454 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 394 shares in the last quarter. 66.63% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals (NASDAQ REGN) opened at $366.96 on Monday. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The firm has a market capitalization of $39,430.00, a PE ratio of 33.33, a P/E/G ratio of 1.41 and a beta of 1.52. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.
WARNING: “$1.48 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://transcriptdaily.com/2018/01/15/1-48-billion-in-sales-expected-for-regeneron-pharmaceuticals-inc-regn-this-quarter.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.